Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia

Data from the CATIE schizophrenia trial sample at baseline

Henry A. Nasrallah, Jonathan M. Meyer, Donald C. Goff, Joseph Patrick McEvoy, Sonia M. Davis, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

402 Citations (Scopus)

Abstract

Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia and hypertension are highly prevalent in populations with schizophrenia, exceeding 50% in some studies; however, there have been few published studies on treatment rates among schizophrenia patients screened for these disorders. Methods: Using the baseline data from subjects (N = 1460) recruited into the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, we examined the point prevalence of diabetes, hyperlipidemia and hypertension treatment at the time of enrollment for the entire cohort and those with fasting laboratory values obtained 8 or more hours since last meal. Results: Rates of non-treatment ranged from 30.2% for diabetes, to 62.4% for hypertension, and 88.0% for dyslipidemia. Nonwhite men were more likely to be treated for DM and dyslipidemia than nonwhite women. Conclusions: These data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Nonwhite women may be especially vulnerable to undertreatment of dyslipidemia and diabetes compared to nonwhite men. The findings here support the need for increased attention to basic monitoring and treatment of cardiovascular risk factors in this vulnerable and often underserved psychiatric population.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalSchizophrenia Research
Volume86
Issue number1-3
DOIs
StatePublished - Sep 1 2006

Fingerprint

Dyslipidemias
Antipsychotic Agents
Schizophrenia
Clinical Trials
Hypertension
Hyperlipidemias
Therapeutics
Vulnerable Populations
Psychiatry
Meals
Fasting
Primary Health Care
Cardiovascular Diseases
Morbidity
Mortality
Population

Keywords

  • CATIE
  • Health disparities
  • Metabolic disorders
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia : Data from the CATIE schizophrenia trial sample at baseline. / Nasrallah, Henry A.; Meyer, Jonathan M.; Goff, Donald C.; McEvoy, Joseph Patrick; Davis, Sonia M.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 86, No. 1-3, 01.09.2006, p. 15-22.

Research output: Contribution to journalArticle

Nasrallah, Henry A. ; Meyer, Jonathan M. ; Goff, Donald C. ; McEvoy, Joseph Patrick ; Davis, Sonia M. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia : Data from the CATIE schizophrenia trial sample at baseline. In: Schizophrenia Research. 2006 ; Vol. 86, No. 1-3. pp. 15-22.
@article{bb8a50366ede4e1f98fd06f6e92c1c48,
title = "Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline",
abstract = "Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia and hypertension are highly prevalent in populations with schizophrenia, exceeding 50{\%} in some studies; however, there have been few published studies on treatment rates among schizophrenia patients screened for these disorders. Methods: Using the baseline data from subjects (N = 1460) recruited into the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, we examined the point prevalence of diabetes, hyperlipidemia and hypertension treatment at the time of enrollment for the entire cohort and those with fasting laboratory values obtained 8 or more hours since last meal. Results: Rates of non-treatment ranged from 30.2{\%} for diabetes, to 62.4{\%} for hypertension, and 88.0{\%} for dyslipidemia. Nonwhite men were more likely to be treated for DM and dyslipidemia than nonwhite women. Conclusions: These data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Nonwhite women may be especially vulnerable to undertreatment of dyslipidemia and diabetes compared to nonwhite men. The findings here support the need for increased attention to basic monitoring and treatment of cardiovascular risk factors in this vulnerable and often underserved psychiatric population.",
keywords = "CATIE, Health disparities, Metabolic disorders, Schizophrenia, Treatment",
author = "Nasrallah, {Henry A.} and Meyer, {Jonathan M.} and Goff, {Donald C.} and McEvoy, {Joseph Patrick} and Davis, {Sonia M.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.schres.2006.06.026",
language = "English (US)",
volume = "86",
pages = "15--22",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia

T2 - Data from the CATIE schizophrenia trial sample at baseline

AU - Nasrallah, Henry A.

AU - Meyer, Jonathan M.

AU - Goff, Donald C.

AU - McEvoy, Joseph Patrick

AU - Davis, Sonia M.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia and hypertension are highly prevalent in populations with schizophrenia, exceeding 50% in some studies; however, there have been few published studies on treatment rates among schizophrenia patients screened for these disorders. Methods: Using the baseline data from subjects (N = 1460) recruited into the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, we examined the point prevalence of diabetes, hyperlipidemia and hypertension treatment at the time of enrollment for the entire cohort and those with fasting laboratory values obtained 8 or more hours since last meal. Results: Rates of non-treatment ranged from 30.2% for diabetes, to 62.4% for hypertension, and 88.0% for dyslipidemia. Nonwhite men were more likely to be treated for DM and dyslipidemia than nonwhite women. Conclusions: These data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Nonwhite women may be especially vulnerable to undertreatment of dyslipidemia and diabetes compared to nonwhite men. The findings here support the need for increased attention to basic monitoring and treatment of cardiovascular risk factors in this vulnerable and often underserved psychiatric population.

AB - Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia and hypertension are highly prevalent in populations with schizophrenia, exceeding 50% in some studies; however, there have been few published studies on treatment rates among schizophrenia patients screened for these disorders. Methods: Using the baseline data from subjects (N = 1460) recruited into the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, we examined the point prevalence of diabetes, hyperlipidemia and hypertension treatment at the time of enrollment for the entire cohort and those with fasting laboratory values obtained 8 or more hours since last meal. Results: Rates of non-treatment ranged from 30.2% for diabetes, to 62.4% for hypertension, and 88.0% for dyslipidemia. Nonwhite men were more likely to be treated for DM and dyslipidemia than nonwhite women. Conclusions: These data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Nonwhite women may be especially vulnerable to undertreatment of dyslipidemia and diabetes compared to nonwhite men. The findings here support the need for increased attention to basic monitoring and treatment of cardiovascular risk factors in this vulnerable and often underserved psychiatric population.

KW - CATIE

KW - Health disparities

KW - Metabolic disorders

KW - Schizophrenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33747180826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747180826&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2006.06.026

DO - 10.1016/j.schres.2006.06.026

M3 - Article

VL - 86

SP - 15

EP - 22

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -